Interlaboratory variation in the detection of HPA‐specific alloantibodies and in molecular HPA typing

Background and Objectives  Platelet immunology quality assurance exercises have been organized by National Institute for Biological Standards and Control since 1991 and, as of 2006, 35 laboratories participate in the serology section. Molecular human platelet antigen (HPA) typing has been included in the exercises since 1998 and, as of 2006, 29 laboratories participate in this part of the exercise. This report details the performance of laboratories in these two areas.

[1]  W. Ouwehand,et al.  Report on the 13th International Society of Blood Transfusion Platelet Immunology Workshop , 2007, Vox sanguinis.

[2]  W. Ouwehand,et al.  Collaborative studies to establish the first World Health Organization International Standard for detection of human antibody against human platelet antigen‐3a , 2007, Vox sanguinis.

[3]  W. Ouwehand,et al.  Management and outcome of 200 cases of fetomaternal alloimmune thrombocytopenia , 2007, Transfusion.

[4]  W. Ouwehand,et al.  Microarray‐based genotyping for blood groups: comparison of gene array and 5′‐nuclease assay techniques with human platelet antigen as a model , 2005, Transfusion.

[5]  S. Santoso,et al.  Relevance of the HPA‐15 (Gov) polymorphism on CD109 in alloimmune thrombocytopenic syndromes , 2005, Transfusion.

[6]  E. Favaloro,et al.  External quality assurance of DNA testing for thrombophilia mutations. , 2005, American journal of clinical pathology.

[7]  R. W. Huff,et al.  Severe neonatal alloimmune thrombocytopenia caused by antibodies to human platelet antigen 3a (Baka) detectable only in whole platelet assays , 2003, Transfusion.

[8]  T. Barrowcliffe,et al.  Collaborative studies to establish the first WHO Reference Reagent for detection of human antibody against human platelet antigen‐5b , 2003, Vox sanguinis.

[9]  P. Mannucci,et al.  Relatively Poor Performance of Clinical Laboratories for DNA Analyses in the Detection of Two Thrombophilic Mutations – A Cause for Concern , 2002, Thrombosis and Haemostasis.

[10]  W. Ouwehand,et al.  Genotyping for platelet‐specific antigens: techniques for the detection of single nucleotide polymorphisms , 2002, Vox sanguinis.

[11]  W. Ouwehand,et al.  Detection of Gov system antibodies by MAIPA reveals an immunogenicity similar to the HPA‐5 alloantigens , 2000, British journal of haematology.

[12]  S. Kitchen,et al.  A UK National External Quality Assessment Scheme (UK Neqas) for Molecular Genetic Testing for the Diagnosis of Familial Thrombophilia , 1999, Thrombosis and Haemostasis.

[13]  D. Allen,et al.  Interlaboratory variation in the detection of clinically significant alloantibodies against human platelet alloantigens , 1997, British journal of haematology.

[14]  D. Wernet,et al.  Limits of the MAIPA assay when differentiating high-titered platelet-reactive antibodies. , 1997, Beitrage zur Infusionstherapie und Transfusionsmedizin = Contributions to infusion therapy and transfusion medicine.

[15]  W. Ouwehand,et al.  Sensitivity of the platelet immunofluorescence test (PIFT) and the MAIPA assay for the detection of platelet‐reactive alloantibodies: a report on two U.K. National Platelet Workshop Exercises 1 , 1994, Transfusion medicine.